All In Biotech

NDA 019952 · B Braun

Heparin Sodium 25,000 Units In Dextrose 5% In Plastic Container

Heparin Sodium · Injection

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jul 20, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

723

648 serious, 145 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

Heparin Sodium in 5% Dextrose Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin sodium is indicated for: ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation; Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism; Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Mechanism: Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 20, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 4,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective319
  • general physical health deterioration86
  • hyponatraemia85
  • stress85
  • multiple organ dysfunction syndrome84
  • sepsis84
  • abdominal pain79
  • ascites78
  • ventricular fibrillation78
  • abdominal distension77
  • appendicitis77
  • appendicolith77

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20126
20132
20153
201622
201723
201845
201932
202029
202162
202254
2023163
2024202
202547
202632

Recalls

3 FDA enforcement reports for this application.

  • May 9, 2023 · Class II · Terminated

    Subpotent: Low anti-factor IIa Potency.

  • Mar 1, 2023 · Class II · Terminated

    Subpotent Drug: low Anti-Factor IIa potency.

  • Jun 13, 2019 · Class II · Terminated

    Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,572 on PubMed

Sponsor: B Braun · Also marketed as Heparin Sodium 20,000 Units In Dextrose 5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.